Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

NexLife vs NP2GO

By GLP-1 ScorecardUpdated

NexLife
Site position #317

Lower grade

NP2GO
Site position #37

Higher grade

Score comparison

NP2GO has the higher recorded score — 80.2/100 to 61.9/100.

NP2GO grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Both molecules across 40 states, but upper-mid pricing and no verification listing.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueNP2GO +10
71
81
Dose & formulationNP2GO +16
64
80
Clinical oversightNP2GO +24
55
79
Labs & monitoringNP2GO +25
53
78
FulfillmentNP2GO +15
67
82
Contract termsNP2GO +27
55
82
NexLife · top barNP2GO · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricNexLifeNP2GO
WeighScore61.9/10080.2/100
GradeCB−
Site position#317#37
Semaglutide$165/mo (compounded)$150/mo
Tirzepatide$215/mo (compounded)$250/mo
CoverageCoverage not published40 states
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedNot confirmed
NexLife

Site position #317 · C

FDAWarning letter issued to Nexlife Inc. dba Nexlife in June 2026. See the FDA warning-letter database.

Strengths

  • LegitScript certified platform
  • Works exclusively with LegitScript-certified, NABP-accredited pharmacies — strongest pharmacy trust signal in the dataset
  • Both semaglutide and tirzepatide at competitive pricing
  • Semaglutide from $145/mo on the 12-month plan ($165/mo month-to-month) - among the lowest in the dataset

What to consider

  • State availability not publicly disclosed
  • Compounded only — no brand-name options
  • Also covers hormone optimization and longevity
  • Lowest advertised rates ($145 sema / $186 tirz) require a 12-month plan commitment
  • FDA issued Nexlife Inc. dba Nexlife a warning letter in June 2026; the letter is public in FDA's warning-letter database
NP2GO

Site position #37 · B−

Strengths

  • Both molecules
  • 40-state footprint
  • Transparent listed pricing

What to consider

  • Independent LegitScript certification has not been verified for this review
  • Upper-mid pricing ($150/$250)
  • Not all 50 states

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard